These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36925667)

  • 1. A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients.
    Youssef D; Richards S; Lague S; Sheppard C; Smith J; Vorhies E; Hosking M; Pietrosanu M; Bates A
    Front Pediatr; 2023; 11():1055158. PubMed ID: 36925667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
    Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
    J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients.
    Cui X; Lu W; Zhang D; Qie L; Li H; Li X; Liu H; Ji Q
    Front Cardiovasc Med; 2022; 9():991586. PubMed ID: 36204579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
    Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
    Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
    Kim NH; Hemnes AR; Chakinala MM; Highland KB; Chin KM; McLaughlin V; Zhao C; Narayan V; Farber HW
    J Heart Lung Transplant; 2021 Apr; 40(4):279-288. PubMed ID: 33526303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selexipag Dosing Strategies for Pediatric Patients with Pulmonary Arterial Hypertension.
    Grossman M; Walker S; Ramsey EZ
    Pediatr Cardiol; 2024 May; ():. PubMed ID: 38727824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selexipag for the Treatment of Pediatric Pulmonary Hypertension: A Systematic Review.
    Li M; Liu L; Liu C; Chen Z; Li W; Li X; Ma X; Zhang Y
    Clin Ther; 2024 Jan; 46(1):59-68. PubMed ID: 37945502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: Rescue treatment with add-on selexipag in a preterm infant with suprasystemic pulmonary hypertension, pulmonary capillary hemangiomatosis, and isolated pulmonary vein stenosis.
    Hasan H; Hysko K; Jack T; Dingemann J; Wetzke M; Hansmann G
    Front Cardiovasc Med; 2022; 9():984698. PubMed ID: 36568561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience.
    Youssef DE; Handler SS; Richards SM; Sheppard CA; Smith J; Tillman K; Pietrosanu M; Kirkpatrick E; Bates A
    Front Pediatr; 2023; 11():1055131. PubMed ID: 36776903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension.
    Geerdink LM; Bertram H; Hansmann G
    Pulm Circ; 2017; 7(2):551-554. PubMed ID: 28597771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration.
    Faircloth JM; Bhatt ND; Chartan CA; Coleman RD; Villafranco N; Ruiz FE; Morales-Demori R; Whalen E; Ely E; Fombin R; Varghese NP
    Front Pediatr; 2023; 11():1050508. PubMed ID: 36969286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
    Klose H; Chin KM; Ewert R; Gall H; Parambil J; Poch D; Seyfarth HJ; Axelsen LN; Hsu Schmitz SF; Stein C; Preston IR
    Respir Res; 2021 Feb; 22(1):34. PubMed ID: 33536021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension.
    Rothman A; Cruz G; Evans WN; Restrepo H
    Pulm Circ; 2020; 10(1):2045894019876545. PubMed ID: 32110381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.
    Takatsuki S; Nakayama T; Shimizu Y; Kawai R; Matsuura H
    Cardiol Young; 2023 Feb; 33(2):196-200. PubMed ID: 35383553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
    PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
    Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM
    Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.